Research programme: live bacterial therapeutics - Microbiotica
Latest Information Update: 19 May 2022
At a glance
- Originator Microbiotica
- Class Bacteria
- Mechanism of Action Bacteria replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 20 Apr 2022 Research programme: live bacterial therapeutics - Microbiotica is available for licensing as of 20 Apr 2022. https://microbiotica.com/
- 20 Apr 2022 Early research in Unspecified in United Kingdom (PO) (Microbiotica pipeline, April 2022)